Sitagliptin in Recurrent/Progressive Grade 4 Glioma
United States45 participantsStarted 2026-06-11
Plain-language summary
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Hemoglobin ≥ 9 g/dl
. Absolute neutrophil count ≥ 1,500/mcL
. Platelet count ≥ 100,000/mcL
. Total bilirubin \< 1.5 x institutional upper limit of normal (ULN)
. AST (SGOT) ≤ 3 X institutional ULN
. ALT (SGPT) ≤ 3 X institutional ULN
. Calculated creatinine clearance \> 50 mL/min
. Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Phase Ib: Dose-limiting toxicities as measured by CTCAE v5.0
Timeframe: First day of treatment through completion of cycle 2 of therapy (each cycle is 28 days)
2
Pilot: Change in participants' concentration of circulating MDSCs with treatment
Timeframe: From pre- to post-treatment (end of post-op cycle 1; each cycle is 28 days).